Skip to Main Content

A rare inherited form of early-onset dementia that typically strikes people between the ages of 45 and 65 is the focus of a new biotech startup that officially launched Thursday.

Arkuda Therapeutics of Cambridge, Mass., has been incubated by Atlas Venture since February of last year. It has $44 million in venture capital raised by Atlas and the venture capital arm of Pfizer, the pharmaceutical giant.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED